Xu Wen-Fang, Wu Yong, Pan Guo-Shao, Zhong Jian-Ping, Lan Shao-Bo, Chen Xue-Fang, Lu Qiu-Qiong
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Feb;34(2):157-61.
To explore the effect of Qiling Decoction (QD) combined highly active antiretroviral treatment (HAART) on expression levels of peripheral blood Th17 and Treg cells in HIV/AIDS patients.
Totally 55 HIV/AIDS patients were randomly assigned to the treatment group (28 cases) and the combination group (27 cases). Besides, 21 HIV negative patients were recruited as the healthy control group. Those in the treatment group received HARRT alone, while those in the combination group received HAART combined QD. The observation lasted for 24 weeks. Meanwhile, according to peripheral blood CD4+ T cell counts before treatment, HIV/AIDS patients were assigned to three subgroups. For patients in subgroup 1, 1 cells/microL < CD4+ T cell counts < or = 100 cells/microL; For patients in subgroup 2, 101 cells/microL < CD4+ T cell counts < or = 200 cells/lL; For patients in subgroup 3, 201 cells/microL < CD4+ T cell counts < or = 350 cells/microL. Expression of peripheral blood Th17 and Treg cells, and number of CD4+ T cell counts were detected using flow cytometry (FCM)in HIV/AIDS patients at the pre-treatment baseline, week 4, 12, and 24, as well as those in the healthy control group.
Compared with the healthy control group, CD4+ T cell counts and the baseline expression level of Th17 cells in the peripheral blood of HIV/AIDS patients significantly decreased, the expression level of Treg cells significantly increased P < 0.01). Compared with before treatment in the same group, CD4+ T cell counts all increased at week 4, 12, and 24 in the two treatment groups, showing statistical difference (P < 0.05, P < 0.01). There was no statistical difference in the effective rate at various CD4+ T cell levels between the two groups (P > 0.05). There was no statistical difference in expression levels of Th17 and Treg cells between the combination group and the treatment group at any time point (all P >0.05). The Th17/Treg ration significantly increased in the combination group after 24 weeks of treatment, showing statistical difference when compared with the treatment group (U = 2.135, P = 0.038).
QD could improve the immune balance of Th17/Treg cells, which might be one of its mechanisms for improving HIV/AIDS patients' immunity.
探讨芪苓汤（QD）联合高效抗逆转录病毒治疗（HAART）对HIV/AIDS患者外周血Th17和Treg细胞表达水平的影响。
将55例HIV/AIDS患者随机分为治疗组（28例）和联合组（27例）。另外，招募21例HIV阴性患者作为健康对照组。治疗组单独接受HARRT，联合组接受HAART联合QD治疗。观察持续24周。同时，根据治疗前外周血CD4+T细胞计数，将HIV/AIDS患者分为三个亚组。亚组1患者，1个细胞/微升＜CD4+T细胞计数≤100个细胞/微升；亚组2患者，101个细胞/微升＜CD4+T细胞计数≤200个细胞/微升；亚组3患者，201个细胞/微升＜CD4+T细胞计数≤350个细胞/微升。在治疗前基线、第4周、12周和24周，使用流式细胞术（FCM）检测HIV/AIDS患者以及健康对照组外周血Th17和Treg细胞的表达情况和CD4+T细胞计数。
与健康对照组相比，HIV/AIDS患者外周血CD4+T细胞计数及Th17细胞基线表达水平显著降低，Treg细胞表达水平显著升高（P＜0.01）。与同组治疗前相比，两个治疗组在第4周、12周和24周时CD4+T细胞计数均升高，差异有统计学意义（P＜0.05，P＜0.01）。两组在各CD4+T细胞水平的有效率无统计学差异（P＞0.05）。联合组与治疗组在任何时间点的Th17和Treg细胞表达水平均无统计学差异（均P＞0.05）。联合组治疗24周后Th17/Treg比值显著升高，与治疗组相比差异有统计学意义（U = 2.135，P = 0.038）。
芪苓汤可改善Th17/Treg细胞的免疫平衡，这可能是其改善HIV/AIDS患者免疫力的机制之一。
Zotero 插件